Fig. 1 | Eliminating tumors with macrophage–drug conjugates. ICD, immunogenic cell death. The process is enhanced by the drug component, which directly kills cancer cells and creates debris for ...

One of their key attributes is their mobility to sites of inflammation, infection, and tumors. This trait garnered the attention of researchers who developed therapies to leverage macrophages’ ...

umors use chemokine signals to draw monocytes and tissue-resident macrophages into the tumor microenvironment, where the cells become tumor-associated macrophages (TAMs). Once believed to be wholly ...

However, the clinical efficacy of these therapies is still limited, mainly owing to the hostile tumor ... related macrophages by binding to a macrophage-specific C-type lectin DC-SIGN, making ...

Additionally, researchers found that an increase in a type of mesenchymal-like tumor cells was linked to poorer responses in chemotherapy. Certain immune cells (e.g. macrophages) became more ...